CLAIMS

1. A liquid pharmaceutical composition comprising semaglutide, no more than 0.1 %(w/w) phenol and above 6.4 mg/ml sodium chloride and optionally further comprising histidine.
2. The liquid pharmaceutical composition according to any one of the previous claims comprising no phenol.
3. The liquid pharmaceutical composition according to claim 1 consisting essentially of a) semaglutide, optionally b) no more than 0.1 %(w/w) phenol, c) above 6.4 mg/ml sodium chloride, d) buffer, e) at least 60% water, optionally f) histidine, and optionally g) one or more agents for adjusting pH, such as HCl, NaOH, or acetate
4. The liquid pharmaceutical composition according to claim 1 or 2 comprising 0.5–10 mg/ml semaglutide and 8.1-12 mg/ml sodium chloride.
5. The liquid pharmaceutical composition according to any one of the previous claims comprising 8.2-8.9 mg/ml sodium chloride.
6. The liquid pharmaceutical composition according to any one of the previous claims further comprising histidine.
7. The liquid pharmaceutical composition according to any one of the preceding claims comprising 0.5-3.5 mg/ml semaglutide, such as 3.2 mg/ml semaglutide.
8. The liquid pharmaceutical composition according to any one of the previous claims, wherein said liquid pharmaceutical composition further comprises a buffer, such as wherein said buffer is present in a concentration of 0.01-50 mM.
9. The liquid pharmaceutical composition according to any one of the previous claims, wherein said buffer is a phosphate buffer and wherein the concentration of said phosphate buffer is optionally 1-2 mg/ml.
10. The liquid pharmaceutical composition according to any one of the previous claims, wherein said liquid pharmaceutical composition has a pH in the range of 6.0-10.0, such as 7-8.
11. The liquid pharmaceutical composition according to any one of the previous claims, wherein said liquid pharmaceutical composition is for parenteral administration.
12. The liquid pharmaceutical composition according to any one of the previous claims comprising 0.5-3.5 mg/ml semaglutide, 8.25 mg/ml sodium chloride and 1.42 mg/ml disodium hydrogen phosphate dihydrate.
13. A kit comprising a liquid pharmaceutical composition according to any of claims 1-12 and an injection device for administration of said composition to a subject.

14. The kit according to claim 14, wherein said injection device comprises a needle and may be a pre-filled syringe.
15. A liquid pharmaceutical composition according to any of claims 1-12 for use in medicine, such as for use in the treatment and/or prevention of diabetes, obesity, Alzheimer's disease, NASH and/or cardiovascular diseases.